EyePoint completes enrollment in both Phase 3 DME trials of DURAVYU; topline data Q4 2027

EyePoint, Inc.

Over 480 patients enrolled across COMO and CAPRI trials in five months, ahead of schedule.
Topline 56-week data for both DME trials anticipated in Q4 2027.
DSMC reviewed masked safety data in May 2026 and recommended continuation of both programs.
DURAVYU evaluated in over 190 patients across four completed trials with favorable safety profile.
Phase 3 program developed in alignment with FDA and EMA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.